No cancer or care plan is the same. Every patient is unique. Their risk level is just as individual.
Knowing that datapoint is the key for improving their prostate cancer screening and diagnosis.
The Clear, Accurate Insight You Need
Healthcare providers deserve an easy and accurate risk screening test to provide improved insights and decision making. Men need to know their risk of clinically significant prostate cancer based on their specific genetic history and individualized clinical needs.
A Solution for Providers
You want to provide the least invasive, best care for your patient at the right time in their healthcare journey. The foundation of MPS2, novel gene fusion T2:ERG, is present in most men with prostate cancer and is the most specific prostate cancer biomarker.
Combined with 17 other prostate cancer genetic transcripts, MPS2 offers a precision medicine solution for men who are considered to have an increased risk for prostate cancer, revealing his individualized risk score with market leading accuracy and stratified insights.
A Solution for Patients
Early detection makes the difference for you and your family. A simple 30-second urine test can provide you an individualized risk score for clinically significant prostate cancer based on your genes.
The personalized score gives you and your doctor clear and accurate insights to discuss and decide on next steps that are best for you.
Most men with an elevated PSA
will have a prostate biopsy negative
for clinically significant cancer.
An elevated Prostate-Specific Antigen (PSA) can be concerning. But PSA can be elevated for many reasons aside from cancer. PSA testing is inconclusive and can leave unanswered questions.
Less than 25% of men with an elevated PSA will have clinically significant prostate cancer.
That means more than 75% of men with an elevated PSA will have a negative biopsy and may require a different path of care based on their personalized risk level.
Why Does a Personalized Risk Score Matter?
Each patient is unique. Precision medicine is the key to providing the best care at the right time.
How Does MPS2 Risk Assessment Work?
30 seconds can make a difference. Enhancing the accuracy of prostate cancer screening and care decisions is as simple as a non-invasive, post-DRE urine test. Improve your experience by bringing clarity to a generic and inconclusive process. You deserve the next generation in prostate cancer risk assessment.
